The study by Sivori et al., 2021, highlights the potential of BiKEs and TriKEs, particularly those targeting CD16 on NK cells and TAAs such as CD33, EpCAM, and CD133 on tumor cells (107). The gene discussed is FCGR3A; the disease is neoplasm.